We also obtained an independent validation of our findings through AD-related biomarkers, with mLOY phenotypes associated with higher levels of total tau and p-tau in the CSF and displaying the proteomic neurodegenerative biochemical signature observed with other AD-related factors (Figure 3). Here, MAPT is linked to Alzheimer disease.